PDCD1 and neoplasm: Additionally, intrinsic Anti-Silencing Function 1A Histone Chaperone (ASF1A) deficiency in tumor cells can enhance anti-PD-1 therapy efficacy by upregulating Granulocyte–Macrophage Colony-Stimulating Factor (GM-CSF) expression [126].